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Accompanied by the improvement in the public health and medical care, the life span 
of human beings has elongated considerably over the last decades. Consequently, 
the prevalence of aging-associated diseases has also increased. Age-related alterations 
of the central nervous system include general morphological changes and functional 
deterioration as well as increased incidence of neurodegenerative diseases. 
Neuroinflammation, which also increases during aging, could be an important link or 
a common feature for healthy aging and neurodegenerative diseases. Microglia, the local 
immune cells in the CNS, are the key cellular mediators of neuroinflammatory processes. 
The aim of this thesis is to explore phenotypical and functional changes of microglia in 
aging-associated neurodegenerative diseases. In chapter 2, we observed hyperreactivity 
of Aβ plaque-associated microglia upon systemic inflammation in transgenic AD mouse 
models (i.e., 5XFAD and APP23). We investigated the gene expression profiling of Aβ 
plaque-associated microglia of 5XFAD mice. The upregulated genes were involved in 
biological processes including immune response to external stimulus, cell motility, and 
cell differentiation. Next, we observed that the expression of phagocytic markers and 
AD-associated genes was higher in laser-captured EOAD plaques than that in LOAD 
plaques. Aβ plaque-associated microglia are the primary source of neuroinflammation 
related to AD pathology. In chapter 3, we found a profound gene expression pattern 
related to pro-inflammatory processes, phagocytosis and lipid homeostasis in microglia 
isolated from the aging mouse brain, compared to young microglia. An abundant 
expression of microglia phagocytic markers was found particularly in the white 
matter of aging mouse brain. Using human post-mortem samples, we observed 
that early inflammatory activity starts to appear in white matter at middle age. We 
further provided evidence that microglia-induced neuroinflammation is predominant 
in the white matter of aging and EOAD brains. Neuroinflammation may contribute 
to the progression of neurodegeneration, and have prognostic value for detecting 
the onset and progression of aging and neurodegeneration. In chapter 4, we observed 
the morphological changes and proliferation of microglia in HFD mice in the cortex, 
hypothalamus, and cerebellum. However, the change of diet didn’t alter the microglial 
reaction towards peripheral administration of LPS. Finally, we observed that LFD, 
combined with calorie restriction could decrease the expression of phagocytic markers 
in the white matter microglia of the aging brain. Our study indicates the protective 
role of calorie restriction during aging-related decline. In chapter 5, we describe 
neuromuscular pathology in a novel transgenic tauopathy mouse strain with enhanced 
neuron-specific expression of P301S mutant tau.  We observed that motor deficits 
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already appeared in Tau 58/4 mice 3 months after birth and deteriorated during aging. 
During aging, we observed a significant denervation of the neuromuscular junction and 
muscle hypotrophy in the EDL muscle from Tau 58/4 mice. Using electron microscopy, 
we observed ultrastructural changes in the sciatic nerve of Tau 58/4 mice indicative of 
the loss of large axonal fibers and hypomyelination. We also observed increased glia 
activity in the corticospinal tract of the spinal cord in Tau 58/4 mice. We conclude that 
the accumulated hyperphosphorylated tau aggregates in axonal terminals may induce 
‘dying-back axonal degeneration’, myelin abnormalities, neuromuscular junction 
denervation, and muscular atrophy, which may be the mechanisms responsible for 
the deterioration of the motor function in Tau 58/4 mice. 
Immune hyperreactivity in Aβ plaque-associated microglia 
There is a long-lasting discussion on the function and phenotype of Aβ plaque-
associated microglia in AD. Previous studies show that Aβ plaque-associated 
microglia reduced their capacity in phagocytosis in vitro (Hellwig et al., 2015), but 
they upregulated inflammatory markers and inflammasome activity (Heneka et al., 
2013). In acute hippocampal brain slices, the processes of plaque-associated microglia 
show hypermotility (Gyoneva et al., 2016). However, the microglial process motility 
towards the tissue lesion or damage site is suppressed in transgenic AD mouse models 
(Gyoneva et al., 2016; Krabbe et al., 2013). In chapter 2, we observed the upregulation 
of phagocytic markers and AD-associated genes (e.g., Axl, MHC II/HLA-DRa, Apoe, 
Trem2, and TyroBp) in Aβ plaque-associated microglia in transgenic AD mouse 
models and in human EOAD. The Aβ plaque-associated microglia in APP23 and 
5XFAD mice secreted a substantial IL-1β after i.p. Injection of LPS. Gene expression 
profiling of MHC II+ microglia (representing Aβ plaque-associated microglia) showed 
the upregulated genes involved in the biological processes (gene ontology terms) 
including “immune response to external stimulus” (e.g., Axl, CD63, Egr2, and Lgals3), 
“cell motility” (e.g., Ccl3, Ccl4, Cxcr4, and Sdc3), “cell differentiation”, and “system 
development” (e.g., St14, Trpm1, and Spp1). Our results point out Aβ plaque-associated 
microglia as a proinflammatory phenotype, which resembles “primed microglia”. 
Recently, a distinctive electron-dense “dark microglia” has been discovered at several 
pathological conditions, e.g., chronic stress, aging, and AD. In the vicinity of Aβ plaques 
of APP/PS1 mice, these “dark microglia” are more active in engulfing dendritic spines, 
axon terminals, and synapses (Bisht et al., 2016). It could well be that Aβ plaque-
associated microglia are comparable to these “dark microglia”. However, studies on 
the origin and characterization of “dark microglia” in either transgenic AD mouse 
models or AD patients are lacking. It may be an interesting topic in future. Besides, we 
will further investigate the gene expression profile and perform the functional analysis 
of Aβ plaque-associated microglia in human EOAD and LOAD. 
Increased white matter inflammation in aging- and Alzheimer’s disease brain
MRI studies have shown that the white matter in the brain is vulnerable to the aging 
environment (Gunning-Dixon et al., 2009). In a recent longitudinal diffusion MR 
imaging trial the white matter changes (i.e., global fractional anisotrophy, mean 
diffusivity, and white matter lesion) of more than 500 people have been recorded over 
a 2-year follow-up interval. The study clearly showed microstructural deterioration 
of the normal-appearing white matter during normal aging (de Groot et al., 2016). 
Besides, white matter damage has also been observed in EOAD and focal AD forms 
and occurs even earlier than cortical atrophy (Caso et al., 2015). In chapter 3, we 
investigated the phenotypical and functional changes of microglia in the white matter 
in the context of aging and Alzheimer’s disease. Interestingly, we observed an abundant 
expression of microglia phagocytic markers (e.g., Mac-2, Axl, CD16/32, Dectin1, 
CD11c, and CD36) particularly in the white matter of 24-month-old mouse brain. 
Using microglia isolated from white or gray matter-enriched brain regions, RNA 
expression of phagocytosis and activation markers (i.e., Axl, CD36, Clec7a, LgalS3, and 
ApoE) were all significantly higher expressed in the white matter of the aged mice. In 
the human brain, increased microglia activity already starts to show from middle age. 
We also observed that increased microglia activity is prominently present in the white 
matter of EOAD brains, compared to young controls. Microglia activity in the white 
matter might have prognostic value for detecting the onset and progression of aging 
and neurodegeneration in future.
White matter pathology is also related to cognitive impairment
During aging, the white matter in the brain is characterized by pathological alterations, 
e.g., mild astrocytic gliosis and partial loss of myelin, axons, and oligodendrocytes. 
Previous studies have shown that white matter pathology is related to cognitive 
impairment (e.g., global cognition (Longstreth et al., 1996; Prins et al., 2005) and 
information processing speed (Prins et al., 2005; Ylikoski et al., 1993)). Meta-analysis 
of longitudinal studies has demonstrated that the cognitive decline parallels white 
matter hyperintensities in MRI scans (Debette and Markus, 2010). The progression 
in periventricular white matter hyperintensities (PVWMH) volume has also been 
longitudinally associated with the decline in mental processing speed (van den Heuvel 
et al., 2006). The occurrence of PVWMH also indicated an increased risk of dementia 
(Prins et al., 2004). 
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The hypothesized mechanisms for cognitive decline in patients with changes in 
white matter structure include brain atrophy, axonal stress, and small vessel disease. 
Previous studies have shown that the severity of white matter lesions was related 
to the loss of brain volume and cognitive decline (e.g., memory, conceptualization) 
(Schmidt et al., 2005). White matter hyperintensities may associate with Wallerian 
degenerations of axons (Du et al., 2005). Due to the hypoperfusion caused by 
aging and hypertension-related changes of microvessels, microinfarcts occur in 
the white matter.
In future, considering the white matter pathology might be an indicator of cognitive 
impairment (Smith et al., 2008), it would be worthwhile to conduct longitudinal 
studies (including the neuroimaging examination of white matter change/activated 
microglia and cognitive studies) on 1) the carriers of EOAD mutations from early life 
on, when they are still at the preclinical stage; 2) healthy aging people starting at their 
middle age. 
Reversal of inflammatory process in the aging brain by low-fat diet with 
calorie restriction
It has been known that animal models of aging and obesity are characterized by 
inflammation in specific brain regions, e.g., hypothalamus. In chapter 4, we investigated 
microglia phenotypes in different brain regions of mice fed with HFD or LFD. HFD 
could increase the number or soma of microglia in the cortex, hypothalamus, and 
cerebellum. The expression level of genes involved in immune response, phagocytosis, 
and metabolism didn’t change in the hypothalamic microglia of young HFD mice, 
compared to LFD mice. Previous studies have shown that caloric restriction could 
prolong the lifespan of yeast, rodents, and monkeys (Colman et al., 2014; Lee and 
Longo, 2016). Age-related deficits in memory and motor coordination are also 
ameliorated by caloric restriction in rodents (Grayson et al., 2014; Kuhla et al., 2013; 
Vermeij et al., 2016). Caloric restriction could suppress microglial activation and 
prevent neuronal death after cortical injury (Loncarevic-Vasiljkovic et al., 2012). In 
chapter 4, the expression of phagocytic markers in the white matter microglia of aging 
brain was markedly decreased in LFD mice with caloric restriction, which indicates 
the protective role of caloric restriction on microglia function during aging decline. 
Thus, calorie restriction is a non-genetic intervention for successful brain aging.
FUTURE PERSPECTIVE
Trem2 function during AD and aging
Genome-wide association studies have identified rare variants of Trem2 as risk factors 
for LOAD. In chapter 2 and 3, we showed the increase of Trem2 mRNA expression 
surrounding Aβ plaques in transgenic AD mice and in EOAD brains, as well as in 
the white matter of aging brain tissue. It has been postulated that during AD, Trem2 
signaling may control the microglial response to Aβ (Kleinberger et al., 2014; Wang et 
al., 2015). The mechanisms for Trem2 regulating microglial response to Aβ plaques are 
not yet clear. Recent studies provide following possibilities: 1) Trem2 could promote 
phagocytosis and the clearance of apoptotic neurons and Aβ. In parallel, Trem2 limits 
the pro-inflammatory signals which are transmitted by pattern recognition receptors 
upon Aβ (Colonna and Wang, 2016; Takahashi et al., 2005). 2) As a lipid receptor, 
Trem2 senses the changes in the lipid microenvironment during AD owing to cell 
death, synaptic dysfunction, and Aβ production. Trem2 sustains microglial activation 
by PRRs or other receptors to limit Aβ accumulation (Colonna and Wang, 2016; 
Wang et al., 2015). 3) Trem2 expression on peripheral monocytes is required for their 
recruitment and these myeloid cells originated from peripheral blood monocytes 
cluster around Aβ plaques (Jay et al., 2015). Besides its effects in AD, Trem2 also has an 
impact on microglial senescence during aging. Aged TREM2-/- mice have significantly 
reduced the numbers of microglia with an abnormal morphology in the white matter 
(Poliani et al., 2015). 
Recently, soluble Trem2 (sTrem2), the ectodomain of Trem2, which is proteolytically 
cleaved and released into the extracellular space, has gained attention. The level of 
sTrem2 in the cerebral fluid is increased in the early symptomatic phase of AD (Suárez-
Calvet, Kleinberger, et al., 2016) and is associated with the increase in gray matter 
volume in early AD using MRI (Gispert et al., 2016). Interestingly, in patients with 
autosomal dominant AD, the changes in CSF sTrem2 appeared after brain amyloidosis 
and neuronal injury (Suárez-Calvet, Araque Caballero, et al., 2016). sTrem2 might be 
a potential biomarker for microglia activity in neurodegeneration. The function of 
sTrem2 still needs further investigation.  
Anti-β-amyloid immunotherapy for Alzheimer’s disease
In the last decades, based on the “amyloid cascade hypothesis”, various anti-Aβ 
strategies have been pursued as the main direction for the treatment of Alzheimer’s 
disease. The strategies include inhibition of the secretases responsible for Aβ generation 
(Panza et al., 2009), prevention of the aggregation of Aβ deposition, and acceleration 
of the rate of Aβ clearance (C.A. and E., 2010). With respect to the clearance of Aβ, 
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a large number of studies have been designed to investigate the immunotherapy in 
AD. Aβ immunization includes active vaccination (the administration of Aβ antigens) 
and passive vaccination (anti-Aβ antibodies). It was firstly observed that anti-Aβ 
antibodies inhibit fibrillar aggregation of Aβ peptide and prevent the neurotoxic effects 
of Aβ in vitro (Solomon et al., 1996, 1997). In 1999, Schenk et al. reported the first 
evidence that active immunotherapy with Aβ could attenuate AD-like pathology 
in vivo (Schenk et al., 1999). In this study, the researchers vaccinated transgenic 
PDAPP mice with synthetic human Aβ42, which prevented plaque deposition and 
attenuated the gliosis and neuritic dystrophy. Similar findings were observed in various 
transgenic AD mouse models, using different adjuvants and routes of administration 
(Asuni et al., 2006; Lemere et al., 2000; Sigurdsson et al., 2001; Yu et al., 2016). In 
these animal models, active Aβ immunization could not only reduce the Aβ burden 
but also attenuate behavioral deficits (Janus et al., 2000; Morgan et al., 2000; Yu et 
al., 2016). Besides active vaccination, passive Aβ immunotherapy could also prevent 
AD-like pathology in transgenic AD mouse models. Thus passive immunization with 
anti-Aβ monoclonal antibodies lowered the plaque load, reduced neuritic dystrophy, 
and reversed behavioral deficits (Bard et al., 2003; DeMattos et al., 2001; Kotilinek et 
al., 2002). The routes of administration included systemic injection (DeMattos et al., 
2001), intra hippocampal injection (Oddo et al., 2004), and intracerebroventricular 
infusion (Chauhan and Siegel, 2002). The overall efficacy of active Aβ immunotherapy 
might be higher when the immunization occurs at an early stage of AD pathology, even 
before the aggregation of Aβ and tau (C.A. and E., 2010). 
The successful preclinical studies promoted the development of clinical trials of 
immunotherapy in human AD patients. Unfortunately, the first active immunization 
therapy (AN1792) failed because of severe side effects (i.e., meningoencephalitis) 
(Orgogozo et al., 2003). The excessive Th1-mediated response may have been 
the reason for the cytotoxic T-cell reactions surrounding cerebral vessels (Ferrer et 
al., 2004). The second generation of active Aβ immunotherapy (CAD106) now has 
completed its phase IIa trials, and didn’t cause unexpected safety findings, which might 
be a therapeutic option in future (Farlow et al., 2015). Passive Aβ immunotherapy with 
the administration of humanized antibodies seems to avoid induction of Th1-mediated 
autoimmunity (Panza et al., 2014). The monoclonal antibody Bapineuzumab, which 
recognizes the Aβ1-5 region, was shown to lower the brain Aβ burden in a Phase II 
trial (Rinne et al., 2010). However, after two Phase III trials in mild-to-moderate AD 
were completed it appeared that the level of cognitive behavior was not improved 
in the Bapineuzumab-treated AD group (Salloway et al., 2014). Another anti-Aβ 
monoclonal antibody Solanezumab, which is directed against the Aβ13-28 region, 
has finished the Phase III trial. Eli Lilly just announced that patients treated with 
Solanezumab did not show slowing in cognitive decline compared to patients treated 
with placebo in the Phase III trial. Recently, Biogen announced the positive results of 
a Phase II trial of anti-Aβ monoclonal antibody Aducanumab. The brain levels of Aβ 
were reduced in a dose- and time-dependent manner, accompanied by a slowing of 
cognitive decline, during one year of monthly intravenous infusion of Aducanumab 
(Sevigny et al., 2016). Considering the negative results of previous Aβ immunotherapy 
studies, the “Aβ cascade hypothesis” is still under debate (Panza et al., 2014).
CONCLUSION
We have investigated the phenotypical and functional changes of microglia in aging-
associated diseases. Based on the thesis we speculate that misfolded proteins, specific 
brain environment, and dietary changes could affect the microglia phenotype in 
the context of aging and neurodegeneration. We propose that immune hyperreactivity 
of microglia surrounding Aβ plaques and the increased microglia activity in the white 
matter of aging and AD brains could be potential diagnostic and therapeutic targets. 
As a low-fat diet combined with calorie restriction reduced the increased activity of 
microglia in the white matter during aging a protection of the ageing brain by calorie 
restriction seems effective.
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